依特卡肽与西那卡塞对继发性甲状旁腺功能亢进血液透析患者血清甲状旁腺激素的影响:一项随机临床试验
这项随机双盲双模拟试验在683例血清甲状旁腺激素高于500 pg/mL的血液透析患者中比较静脉依特卡肽与口服西那卡塞。治疗26周后,依特卡肽在甲状旁腺激素降低超过30%的比例上非劣于西那卡塞,且达到优效性标准,降低超过50%的比例也更高。
要点
- 依特卡肽在降低甲状旁腺激素超过30%的比例上非劣于西那卡塞(非劣效界值12.0%)。
- 依特卡肽组68.2%患者甲状旁腺激素降低超过30%,西那卡塞组57.7%。
- 依特卡肽组52.4%患者甲状旁腺激素降低超过50%,西那卡塞组40.2%。
核心结论
- 在接受血液透析的中重度继发性甲状旁腺功能亢进患者中,依特卡肽在26周内降低血清甲状旁腺激素浓度方面非劣于西那卡塞,并达到优效性标准。
- 需要进一步研究评估临床结局以及长期疗效和安全性。
研究设计与样本
- 随机、双盲、双模拟活性对照临床试验,比较静脉依特卡肽与口服安慰剂、口服西那卡塞与静脉安慰剂。
- 共纳入683例正在接受血液透析且经活性治疗时血清甲状旁腺激素浓度高于500 pg/mL的患者,来自美国、加拿大、欧洲、俄罗斯和新西兰的164个中心。
- 患者入组时间为2013年8月至2014年5月,随访结束于2015年1月。
- 依特卡肽静脉给药加口服安慰剂组340例,西那卡塞口服加静脉安慰剂组343例,治疗26周;静脉研究药物随血液透析每周给药3次,口服研究药物每日给药。
主要发现
- 主要终点为第20-27周平均透析前甲状旁腺激素浓度较基线降低超过30%的非劣效性(非劣效界值12.0%),依特卡肽非劣于西那卡塞。
- 西那卡塞组343例中198例(57.7%)与依特卡肽组340例中232例(68.2%)达到甲状旁腺激素降低超过30%,两组比例差为-10.5%(95%CI,-17.5%至-3.5%;非劣效性P<.001;优效性P=.004)。
- 依特卡肽组178例(52.4%)达到甲状旁腺激素降低超过50%,西那卡塞组138例(40.2%)(P=.001;比例差12.2%;95%CI,4.7%至19.5%)。
- 最常见的不良反应为血钙降低(依特卡肽组68.9% vs 西那卡塞组59.8%)。
关键数值与推荐
- 主要疗效终点为非劣效性界值12.0%,依特卡肽达到非劣效。
- 甲状旁腺激素降低超过30%的比例:依特卡肽组68.2% vs 西那卡塞组57.7%,比例差-10.5%(95%CI,-17.5%至-3.5%)。
- 甲状旁腺激素降低超过50%的比例:依特卡肽组52.4% vs 西那卡塞组40.2%,比例差12.2%(95%CI,4.7%至19.5%)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需要进一步研究评估临床结局以及长期疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Secondary hyperparathyroidism contributes to extraskeletal calcification and is associated with all-cause and cardiovascular mortality. Control is suboptimal in the majority of patients receiving hemodialysis. An intravenously (IV) administered calcimimetic could improve adherence and reduce adverse gastrointestinal effects. OBJECTIVE: To evaluate the relative efficacy and safety of the IV calcimimetic etelcalcetide and the oral calcimimetic cinacalcet. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, double-dummy active clinical trial was conducted comparing IV etelcalcetide vs oral placebo and oral cinacalcet vs IV placebo in 683 patients receiving hemodialysis with serum parathyroid hormone (PTH) concentrations higher than 500 pg/mL on active therapy at 164 sites in the United States, Canada, Europe, Russia, and New Zealand. Patients were enrolled from August 2013 to May 2014, with end of follow-up in January 2015. INTERVENTIONS: Etelcalcetide intravenously and oral placebo (n = 340) or oral cinacalcet and IV placebo (n = 343) for 26 weeks. The IV study drug was administered 3 times weekly with hemodialysis; the oral study drug was administered daily. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was noninferiority of etelcalcetide at achieving more than a 30% reduction from baseline in mean predialysis PTH concentrations during weeks 20-27 (noninferiority margin, 12.0%). Secondary end points included superiority in achieving biochemical end points (>50% and >30% reduction in PTH) and self-reported nausea or vomiting. RESULTS: The mean (SD) age of the trial participants was 54.7 (14.1) years and 56.2% were men. Etelcalcetide was noninferior to cinacalcet on the primary end point. The estimated difference in proportions of patients achieving reduction in PTH concentrations of more than 30% between the 198 of 343 patients (57.7%) randomized to receive cinacalcet and the 232 of 340 patients (68.2%) randomized to receive etelcalcetide was -10.5% (95% CI, -17.5% to -3.5%, P for noninferiority, <.001; P for superiority, .004). One hundred seventy-eight patients (52.4%) randomized to etelcalcetide achieved more than 50% reduction in PTH concentrations compared with 138 patients (40.2%) randomized to cinacalcet (P = .001; difference in proportions, 12.2%; 95% CI, 4.7% to 19.5%). The most common adverse effect was decreased blood calcium (68.9% vs 59.8%). CONCLUSIONS AND RELEVANCE: Among patients receiving hemodialysis with moderate to severe secondary hyperparathyroidism, the use of etelcalcetide was not inferior to cinacalcet in reducing serum PTH concentrations over 26 weeks; it also met superiority criteria. Further studies are needed to assess clinical outcomes as well as longer-term efficacy and safety. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT1896232.
引用
- Block GA, Bushinsky DA, Cheng S, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017. PMID: 28097356. doi:10.1001/jama.2016.19468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。